The Food and Drug Administration approved Jubilant Life Sciences' new drug for the treatment of hypertension.
Telmisartan tablets represent a generic version of Boehringer Ingelheim Pharmaceuticals' Micardis tablets.
As of June 30, India-based Jubilant holds 70 drug applications filed through the FDA, 44 of which have been approved.
More articles on supply chain:
Medical device, drug recalls soar in Q2
AMA urges Mylan to lower cost of EpiPens
Mylan vows to reduce patient costs in light of EpiPen pricing scandal